Sionna Therapeutics, Inc. SION

Sionna Therapeutics, Inc. (NASDAQ:SION) announced on September 14 that its board approved an approximately 46% workforce reduction as it concentrates development on SION-451 plus SION-2222 for cystic fibrosis. Sionna Therapeutics, Inc. (NASDAQ:SION) ended the second quarter with approximately $268.3 million in cash, cash equivalents, and marketable securities. Management estimates that the workforce reduction, discontinued investment […]

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L consistent with NBD1 biological activity Dual combination Phase 2a trial expected to initiate in first quarter of 2027 46% workforce reduction and other cost-saving measures prioritize advancing the dual combination program and extend cash runway into the second half of 2029 Sionna to host conference call today at 4:30 p.m. ET WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWI

Sionna Therapeutics (SION) is back in focus after reporting topline results for its cystic fibrosis programs, including a Phase 2a proof of concept miss for SION-719 and supportive Phase 1 data for SION-451 combinations. See our latest analysis for Sionna Therapeutics. The Phase 2a miss for SION-719 triggered a sharp reset in sentiment, with Sionna Therapeutics’ share price down 86.8% over the past week and 84.1% year to date. The 1-year total shareholder return has declined 70.1%, indicating...

Sionna Therapeutics recently reported that its lead cystic fibrosis candidate SION-719 failed to meet the key activity endpoint in a Phase 2a proof-of-concept trial as an add-on to Trikafta, prompting the company to stop further development in this setting. At the same time, early-stage data supported advancing SION-451 in combination with SION-2222 while management moves to preserve a roughly US$268.30 million cash balance and reassess the pipeline. We will now examine how discontinuing...

Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid

Sionna Therapeutics stock has fallen sharply in recent sessions, yet the valuation checks suggest it is not a clear bargain even after the sell off. The share price reset sits alongside a low overall value score and a mixed read on what investors are paying for the business today. The stock declined 89.8% over the past week, which signals a major reset in market expectations after recent news. The failure of lead cystic fibrosis candidate SION-719 in a Phase 2a trial can weigh heavily on...

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]

The biotech said it will not advance SION-719 as an add-on therapy after the drug missed its key endpoint in a Phase 2a study

Sionna Therapeutics (NasdaqGM:SION) reported that its lead cystic fibrosis drug candidate failed a Phase 2 trial. The company has halted further development of the candidate and is redirecting resources to other pipeline programs. The outcome removes a potential new competitor to existing cystic fibrosis treatments and marks a major shift in Sionna Therapeutics’ priorities. This kind of abrupt change in a single biotech can be a reminder to also look at more resilient, lower-risk stocks...